berobenatide
Coverage of berobenatide in the Nexus archive.
- Can Monthly Dosing With Novel GLP-1 Maintain Weight Loss?
Updated phase II data from the VESPER program showed that patients achieved weight loss with weekly doses of the investigational GLP-1 agonist berobenatide. The study, presented at the American Diabetes Association annual meeting, is exploring whether monthly dosing can maintain these results.
- Pfizer's monthly weight loss shot posted side effects similar to Wegovy in mid-stage trial
Pfizer's monthly injectable weight loss drug berobenatide showed side effects similar to Novo Nordisk's Wegovy in a mid-stage trial, with comparable rates of nausea and vomiting.
- STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
Pfizer's obesity drug berobenatide, acquired from Metsera, showed continued weight loss when transitioning from weekly to monthly dosing in a mid-stage study. Patients lost up to 12.1% of their weight by 28 weeks, but the rate lagged behind Eli Lilly's Zepbound trial results.